Effects of erythromycin on the rabbit pleura: its potential role as a pleural sclerosant.
Tetracycline (TCN) has been considered the agent of choice for pleurodesis in patients with symptomatic malignant pleural effusions and recurrent pneumothoraces. However, the intravenous form of TCN used for pleurodesis is no longer available. Erythromycin, like TCN, often produces irritation when administered intravenously. In view of these irritant properties, we tested the effect of erythromycin as a pleural sclerosant in rabbits as compared with TCN. Normal saline was used as a control. Adult rabbits weighing 2.5 to 3.0 kg underwent sterile placement of a silastic pleural tube in the right pleural space. Erythromycin (n = 17) or TCN (n = 6), each in doses of 35 mg/kg in 2 ml saline, was administered via the tube. Control animals (n = 6) received 2 ml saline. The chest tubes were left in place for removal of pleural fluid and to maintain lung expansion. Animals were killed 8 d after receiving the various treatments, and their pleural surfaces were examined grossly and histologically. Numerous adhesions were present between the visceral and parietal pleurae in all animals receiving erythromycin and TCN, but not in those receiving saline. On light microscopy, pleurae treated with erythromycin or TCN were histologically identical, showing inflammation, edema, and fibroblast proliferation in the submesothelial tissues. The saline-treated animals had a normal pleura. Because erythromycin produced pleural inflammation and adhesions within 8 d of treatment, we propose that it may have a potential role as a pleural sclerosant.
Carvalho
P
P
Pulmonary Research Laboratory, VA Medical Center, Boise, Idaho 83702-4598.
Knight
L L
LL
Olson
R D
RD
Crowley
J J
JJ
Hawk
P A
PA
Charan
N B
NB
D000818:Animals; D004917:Erythromycin / Q000008:administration & dosage* / Q000627:therapeutic use; D008168:Lung / Q000473:pathology; D010994:Pleura / Q000187:drug effects* / Q000473:pathology; D010996:Pleural Effusion / Q000473:pathology; D018700:Pleurodesis / Q000379:methods*; D011817:Rabbits; D012597:Sclerosing Solutions / Q000008:administration & dosage* / Q000627:therapeutic use; D013752:Tetracycline / Q000008:administration & dosage
D012597:Sclerosing Solutions; D004917:Erythromycin; D013752:Tetracycline